➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Harvard Business School
Baxter
Merck
Moodys

Last Updated: March 4, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Tipifarnib

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Tipifarnib?

Tipifarnib is an investigational drug.

There have been 80 clinical trials for Tipifarnib. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 1999.

The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are National Cancer Institute (NCI), Johnson & Johnson Pharmaceutical Research & Development, L.L.C., and Kura Oncology, Inc.

Recent Clinical Trials for Tipifarnib
TitleSponsorPhase
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialNational Cancer Institute (NCI)Phase 2
Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to TherapyKura Oncology, Inc.Phase 2
Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionSSpanish Lung Cancer GroupPhase 2

See all Tipifarnib clinical trials

Clinical Trial Summary for Tipifarnib

Top disease conditions for Tipifarnib
Top clinical trial sponsors for Tipifarnib

See all Tipifarnib clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Harvard Business School
Baxter
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.